Skip to content

Development and Application of an Oral Care Protocol for Stroke Patients With Orotracheal Intubation

Development and Application of an Oral Care Protocol for Stroke Patients With Orotracheal Intubation

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07690475
Enrollment
60
Registered
2026-07-08
Start date
2026-08-01
Completion date
2027-05-01
Last updated
2026-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Develop an Oral Care Plan and Verify it

Brief summary

Develop a standardized oral care protocol for stroke patients undergoing orotracheal intubation based on evidence-based practice, and validate its effectiveness through clinical trials.

Interventions

Carry out oral care using the constructed standardized oral care plan

OTHERRegular oral care

Carry out oral care using conventional methods

Sponsors

The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed as a patient with stroke;Maintaining an oral tracheal tube insertion;The indwelling time of the oral tracheal tube should be at least 7 consecutive days;No oral diseases before intubation;Tooth count ≥ 10

Exclusion criteria

The patient had been intubated for more than 48 hours before admission;Patients who have had their endotracheal tubes replaced during the procedure;Patients who were discharged halfway through their treatment \-

Design outcomes

Primary

MeasureTime frameDescription
Incidence of Ventilator-Associated Pneumonia (VAP)From intubation until extubation or discharge from ICU, up to 28 days.The incidence of VAP will be assessed and compared between the two groups. Diagnosis will be based on clinical criteria including new or progressive radiographic infiltrates, purulent secretions, fever, and leukocytosis.

Contacts

CONTACTTu HJ juan
1240435911@qq.com+86 1886759508

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 9, 2026